Senior management further increases its stake in EC Healthcare with strong confidence in the future development of the group

0

HONG KONG, February 28, 2022 – (ACN Newswire) – – EC Health (the “Company”, which together with its subsidiaries is referred to as the “Group”, stock code SEHK: 2138), the largest non-hospital medical group in hong kong*, is pleased to announce that the Group’s Chairman and Chief Executive Officer, Mr. Tang Chi Fai further increases stakes after the stake increase announced on January 17. Mr. Tang acquired a total of 605,000 shares of the Company on the market for a total consideration of approximately HK$4.96 million. At January the 21st, Mr. Tang acquired a total of 62,000 shares at an average price of approximately CHF8.49 per share and acquired a total of 543,000 shares at an average price of approximately HK$8.18 to January 22. After the transaction, At Mr. Tang’s stake in the Group’s capital increased to 60.39%

Last year, EC Health has actively entered the healthcare market through organic growth and acquisitions to further consolidate its leading position in the market. As the epidemic rages in hong kong now, the Group also actively provides anti-epidemic medical services to the public through its general outpatient clinics, specialized clinics, health control centers, vaccine centers and laboratory centers. Looking ahead, the Group remains confident of strong long-term business growth momentum and will continue to invest in IT, brand and services to provide better services to the public. »

On EC Health

EC Health East that of Hong Kong leading provider of non-hospital medical services*, relying on its core businesses of preventive and precision medicine, and committed to the development of medical artificial intelligence by integrating its multidisciplinary medical services. This decision, which is based on the Group’s high-end brand image and quality customer services, aims to provide customers with safe and efficient health care and medical services with professionalism. The Group is included in the Hang Seng Composite Index and the MSCI Hong Kong Small Cap Index.

The Group mainly engages in the provision of one-stop medical and healthcare services in Greater China. The Group provides a full range of services and products under its well-known brands, including those of its one-stop provider of aesthetic medical solutions DR REBORN which ranked first in hong kong by sales for years, primary care clinics established jointly with Tencent Doctorate, New York Spine and Physiotherapy Center NYMG Chiropractic Services Center, re:HEALTH Health Management Center, Hong Kong Professional Vaccine HKPV, UMH DENTAL CARE Comprehensive Dental Center, Diagnostic and Imaging Center HKAI, a reVIVE oncology treatment center, a day procedure center HKMED, a specialist clinic SPECIALIST CENTER, NEW MEDICAL CENTER and Prime Medical Centers, specialist in obstetrics and gynecology ZENITH MEDICAL CENTER AND PRENATAL DIAGNOSIS CENTER, specialist center, a PRIME CARE pediatric center, cardiology center HONG KONG INTERNATIONAL CARDIOLOGY CENTER, PathLab Medical Laboratoriesa professional hair care center HAIR FOREST, VIVID EYE ophthalmology center and CE Veterinary Hospital and imaging center.

*According to an independent study conducted by Frost and Sullivan in terms of turnover in 2019 and 2020

Copyright 2022 ACN Newswire. All rights reserved.

© Japan Corporate News, source JCN Press Releases

Share.

Comments are closed.